Skip to search formSkip to main contentSkip to account menu

CHOP regimen

Known as: CTX/DOX/PRED/VCR, ACOP, CHOP 
An abbreviation for a chemotherapy combination that is used to treat non-Hodgkin lymphoma and is being studied in the treatment of other types of… 
National Institutes of Health

Related topics

Related topics

9 relations
CDE protocol-cyclophosphamide/doxorubicin/etoposideCHOP protocol-cyclophosphamide/doxorubicin/prednisone/vincristineCyclophosphamideDoxorubicin

Broader (1)

cisplatin/cyclophosphamide/etoposide protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)
Background: Rituximab (R) plus CHOP (R-CHOP) is standard-of-care treatment for previously untreated diffuse large B-cell lymphoma… 
Highly Cited
2014
Highly Cited
2014
NEDD9 crucially regulates TGF‐β‐triggered epithelial–mesenchymal transition and cell invasion in prostate cancer cells: Involvement in cancer progressiveness
NEDD9 is one of the Crk‐associated substrate (Cas) family proteins that mediate downstream signaling processes including… 
2012
2012
Evaluation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy in antagonizes therapeutic
Purpose— To characterize the importance of cellular Fas-associated death domain (FADD)-like interleukin 1 β -converting enzyme… 
2011
2011
Functional interplay between melatonin receptor‐mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic…
Abstract:  Recently, a novel melatonin MT1 receptor‐mediated antiproliferative signaling mechanism involving transcriptional up… 
2010
2010
Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up
Background: Rituximab induction together with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab… 
Highly Cited
2005
Highly Cited
2005
Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
2004
2004
Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
BACKGROUND AND OBJECTIVES Treatment with CHOP chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma (NHL) is… 
Highly Cited
2003
Highly Cited
2003
Successful Treatment with Erwinia l -Asparaginase for Recurrent Natural Killer/T Cell Lymphoma
We describe a patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell… 
1999
1999
2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger
The aim of the study was to determine the effectiveness of 2-chlorodeoxyadenosine (2-CdA) administered in 2-h i.v. infusions in… 
Highly Cited
1995
Highly Cited
1995
Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
A prospective randomized clinical trial with simultaneous data collection for an economic appraisal was carried out to assess the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)